Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research

Harald Hampel, Marsel M. Mesulam, A. Claudio Cuello, Ara S. Khachaturian, Martin Farlow, Peter J. Snyder, Ezio Giacobini, Zaven S. Khachaturian

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Scientific evidence collected over the past four decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease (AD) is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "cholinergic hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system is one of several interacting systems failures that contribute to AD pathogenesis.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2017

Fingerprint

Translational Medical Research
Cholinergic Agents
Alzheimer Disease
Cholinesterase Inhibitors
Neuroimaging
Cerebral Cortex
Atrophy
Therapeutics
Brain

Keywords

  • Alzheimer's disease
  • Basal forebrain cholinergic system atrophy
  • Cholinergic system
  • Cholinesterase inhibitors
  • Nerve growth factor
  • Nucleus basalis of Meynert (NbM) degeneration

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Revisiting the cholinergic hypothesis in Alzheimer's disease : Emerging evidence from translational and clinical research. / Hampel, Harald; Mesulam, Marsel M.; Cuello, A. Claudio; Khachaturian, Ara S.; Farlow, Martin; Snyder, Peter J.; Giacobini, Ezio; Khachaturian, Zaven S.

In: Alzheimer's and Dementia, 2017.

Research output: Contribution to journalArticle

Hampel, Harald ; Mesulam, Marsel M. ; Cuello, A. Claudio ; Khachaturian, Ara S. ; Farlow, Martin ; Snyder, Peter J. ; Giacobini, Ezio ; Khachaturian, Zaven S. / Revisiting the cholinergic hypothesis in Alzheimer's disease : Emerging evidence from translational and clinical research. In: Alzheimer's and Dementia. 2017.
@article{4a14ee68cb52401b953904a167fad15e,
title = "Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research",
abstract = "Scientific evidence collected over the past four decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease (AD) is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the {"}cholinergic hypothesis of AD{"} and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system is one of several interacting systems failures that contribute to AD pathogenesis.",
keywords = "Alzheimer's disease, Basal forebrain cholinergic system atrophy, Cholinergic system, Cholinesterase inhibitors, Nerve growth factor, Nucleus basalis of Meynert (NbM) degeneration",
author = "Harald Hampel and Mesulam, {Marsel M.} and Cuello, {A. Claudio} and Khachaturian, {Ara S.} and Martin Farlow and Snyder, {Peter J.} and Ezio Giacobini and Khachaturian, {Zaven S.}",
year = "2017",
doi = "10.1016/j.jalz.2017.08.016",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Revisiting the cholinergic hypothesis in Alzheimer's disease

T2 - Emerging evidence from translational and clinical research

AU - Hampel, Harald

AU - Mesulam, Marsel M.

AU - Cuello, A. Claudio

AU - Khachaturian, Ara S.

AU - Farlow, Martin

AU - Snyder, Peter J.

AU - Giacobini, Ezio

AU - Khachaturian, Zaven S.

PY - 2017

Y1 - 2017

N2 - Scientific evidence collected over the past four decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease (AD) is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "cholinergic hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system is one of several interacting systems failures that contribute to AD pathogenesis.

AB - Scientific evidence collected over the past four decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease (AD) is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "cholinergic hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system is one of several interacting systems failures that contribute to AD pathogenesis.

KW - Alzheimer's disease

KW - Basal forebrain cholinergic system atrophy

KW - Cholinergic system

KW - Cholinesterase inhibitors

KW - Nerve growth factor

KW - Nucleus basalis of Meynert (NbM) degeneration

UR - http://www.scopus.com/inward/record.url?scp=85032285662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032285662&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.08.016

DO - 10.1016/j.jalz.2017.08.016

M3 - Article

AN - SCOPUS:85032285662

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -